The dopaminergic and renin angiotensin systems interact to regulate blood pressure. Disruption of the D 3 dopamine receptor gene in mice produces renin-dependent hypertension. In rats, D 2 -like receptors reduce angiotensin II binding sites in renal proximal tubules (RPTs). Because the major D 2 -like receptor in RPTs is the D 3 receptor, we examined whether D 3 receptors regulate angiotensin II type 1 (AT 1 ) receptors in rat RPT cells. The effect of D 3 receptors on AT 1 receptors was studied in vitro and in vivo. The D 3 receptor agonist PD128907 decreased AT 1 receptor protein and mRNA in WKY RPT cells and increased it in SHR cells. PD128907 increased D 3 receptors in WKY cells but had no effect in SHR cells. D 3 /AT 1 receptors colocalized in RPT cells; D 3 receptor stimulation decreased the percent amount of D 3 receptors that coimmunoprecipitated with AT 1 receptors to a greater extent in WKY than in SHR cells. However, D 3 receptor stimulation did not change the percent amount of AT 1 receptors that coimmunoprecipitated with D 3 receptors in WKY cells and markedly decreased the coimmunoprecipitation in SHR cells. The D 3 receptor also regulated the AT 1 receptor in vivo because AT 1 receptor expression was increased in kidneys of D 3 receptor-null mice compared with wild type littermates. D 3 receptors may regulate AT 1 receptor function by direct interaction with and regulation of AT 1 receptor expression. One mechanism of hypertension may be related to increased renal expression of AT 1 receptors due decreased D 3 receptor regulation. (Circ Res. 2006;99:494-500.) 
T he proximal tubule is the major site of sodium and water reabsorption in the mammalian nephron. Paracrine regulation of sodium reabsorption in the proximal tubule by the renin/angiotensin system occurs via several angiotensin receptor subtypes (AT 1 , AT 2 , and AT 4 ). [1] [2] [3] [4] [5] The activation of angiotensin II type 1 (AT 1 ) receptors by angiotensin II increases sodium transport, whereas the activation of AT 2 and AT 4 receptors decreases sodium reabsorption in this nephron segment. [1] [2] [3] [4] [5] However, in physiological conditions, the major effect of angiotensin II on sodium transport is stimulatory, via AT 1 receptors. 1, 2, 6 The dopaminergic system also exerts a paracrine regulatory role on renal sodium transport in the proximal tubule. 7, 8 Dopamine receptors, like the angiotensin II receptors, are expressed in brush border and basolateral membranes of RPTs. 8 -11 In contrast to the stimulatory effect of angiotensin II on sodium transport in RPTs, the major consequence of the activation of dopamine receptors is an inhibition of sodium transport. 7, 8 Inhibition of renal proximal tubular angiotensin II production or blockade of AT 1 receptors increases the natriuretic effect of the D 1 -like agonist, fenoldopam. 11 D 1 -like and D 2 -like receptor agonists also antagonize the stimulatory effect of angiotensin II, acting via AT 1 receptors, on renal proximal tubular luminal sodium transport. 12, 13 The 2 D 1 -like (D 1 and D 5 ) and the 3 D 2 -like (D 2 , D 3 , and D 4 ) receptors are expressed in specific segments of the mammalian kidney. 7,8,14 -19 Whereas the D 4 receptor is expressed mainly in collecting ducts, the D 3 receptor, the major D 2 -like receptor, like the D 1 and D 5 receptors, is expressed in the proximal tubule. [7] [8] [9] [10] The distribution of D 2 receptor protein along the nephron is still uncertain. 8, 19 The effect of D 2 receptors on renal sodium transport is also not clear because of the lack of agonists that are highly selective to the D 2 over the D 3 receptor. 16, 17 However, 7-OH-DPAT, a ligand with a 50-fold selectivity to the D 3 over the D 2 receptor, 16 increases sodium excretion in rats. 17 Moreover, D 3 receptor-null mice have a decreased ability to excrete an acute sodium load, whereas no such limitation is found in D 2 receptor-null mice. 18, 19 We surmise that the D 3 receptor may be the D 2 -like subtype receptor that interacts with the AT 1 receptor in rat RPTs.
Angiotensin and dopamine receptors are expressed in immortalized rat RPT cells. 20, 21 These RPT cells have char-acteristics similar to freshly obtained RPTs and renal brush border membranes, at least, with regard to the D 1 receptors. 9, 10, 21 In this study, we determined whether D 3 receptors interacted with AT 1 receptors. We also examined AT 1 receptor expression in kidneys of D 3 null mice. We now report that D 3 and AT 1 receptors colocalize in rat RPT cells. Furthermore, D 3 receptor occupancy decreases expression of AT 1 receptors and their coimmunoprecipitation with D 3 receptors. The interaction between D 3 and AT 1 receptors also occurs in vivo because AT 1 receptor expression is increased in the kidneys of D 3 receptor-null mice.
Materials and Methods

D 3 Dopamine Receptor-Null Mice
Mice homozygous for the D 3 null receptor were bred from heterozygous mice in C57BL/6 background (The Jackson Laboratory, Bar Harbor, Me); nontransgenic mice served as controls. 18 The mice were anesthetized with pentobarbital (50 mg/kg IP), tracheotomized, and blood pressure determined from the femoral artery. The renal cortices were prepared for immunoblotting as described. 9, 10, 19, 21 All experiments were approved by the Georgetown University Animal Use and Care Committee.
Cell Culture
Immortalized RPT cells from Wistar-Kyoto and spontaneously hypertensive rats (SHRs) 9, 10, 20, 21 were cultured at 37°C in 95% air/5% CO 2 atmosphere in DMEM/F-12. Embryonic thoracic aortic smooth muscle cells 22, 23 (passage 10 to 20) from normotensive Berlin-Druckrey IX (A10; CRL 1476, American Type Culture Collection, Manassas, Va) were cultured at 37°C in 95% air/5% CO 2 atmosphere in DMEM. The cells (80% confluence) were extracted in ice-cold lysis buffer, sonicated, kept on ice for 1 hour, and centrifuged at 16 000g for 30 minutes. All samples were stored at Ϫ70 o until use.
Immunoblotting
Polyclonal rabbit anti-human AT 1 receptor antibodies (QDDCPK-AGRHC, 15 to 24 position on AT 1 receptor) (Santa Cruz Biotechnology Inc, Santa Cruz, Calif) and rabbit anti-rat D 3 receptor antibodies (CHVSPELYR, 405 to 413 position on the D 3 receptor) (Alpha Diagnostic International, San Antonio, Tex) were used. The specificity of these antibodies has been reported. 9,10,24 -26 Rat RPT cells were treated with vehicle, D 3 receptor agonist (PD128907) (Sigma Co, St Louis, Mo) 16 or the D 3 receptor antagonist (U99194A) (Research Biochemicals International, Natick, Mass) 27 at the indicated concentrations and times. To prevent the oxidation of reagents, sodium metabisulfite 28 was used with a final concentration of 200 mol/L in the medium. We designed our experiments so that a time control was not needed for each treatment period. Twenty-six hours before cell lysis for immunoblotting, the cells were starved. Cells were treated with PD128907 for 24, 16, 8, or 2 hours or vehicle, as indicated. At 0 hour, the drug-treated and vehicle-treated cells were prepared for immunoblotting. All cells were incubated for 26 hours; the control cells were incubated with vehicle for 26 hours.
Immunoblotting was performed as previously reported except that the transblots were probed with the D 3 (1:250) or the AT 1 receptor antibody (1:200). 21, 25, 26, 29 The amount of protein transferred onto the membranes was determined by Ponceau-S staining and immunoblotting for ␣-actin (Santa Cruz Biotechnology Inc). The receptor densities were normalized by ␣-actin.
RT-PCR of AT 1 Receptors
A total of 2 to 3 g of total RNA extracted from both WKY and SHR cells was used to synthesize cDNA and served as a template for amplification of AT 1 and for ␤-actin sequences as an endogenous standard. 30 For ␤-actin, the forward primer was 5Ј-GTGGGTATGGGTCAGAAGGA-3Ј and the reverse primer was 5Ј-AGCGCGTAACCCTCATAGAT-3Ј (GenBank accession no. BC 063166). The amplification was performed with the following conditions: 35 cycles of denaturation at 94°C for 2 minutes, annealing for 30 seconds at 52.5°C, and extension for 45 seconds at 72°C. For AT 1 receptor, the forward primer was 5Ј-CCAAAGTCACCTGCATCATC-3Ј and the reverse primer was 5Ј-CACAATCGCCATAATTATCCTA-3Ј (GenBank accession no. NM-030985). The amplification was performed with the following conditions: 35 cycles of denaturation at 94°C for 2 minutes, annealing for 30 seconds at 52.5°C, and extension for 45 seconds at 72°C. 30 The AT 1 receptor mRNA expression was normalized by ␤-actin mRNA.
Immunoprecipitation
RPT cells were incubated with vehicle, or a D 3 receptor agonist, PD128907 (10 Ϫ7 mol/L), for 24 hours as described above. PD128907 has a 10-to 20-fold greater affinity for the D 3 than the D 2 receptor. 16 Cell lysates (800 g protein/mL supernatant) were incubated with D 3 receptor or AT 1 receptor antibody (1 g/mL) for 1 hour and protein-G agarose at 4°C for 12 hours. The immunoprecipitates were suspended in Laemmli buffer, boiled for 10 minutes, divided into 2 aliquots, electrophoresed, transferred, and subjected to immunoblotting with the AT 1 and D 3 receptor antibodies.
In 1 series of experiments, the sample immunoprecipitated with the D 3 receptor antibody was divided into 2 aliquots, 1 immunoblotted with the AT 1 receptor antibody and the other immunoblotted with the D 3 receptor antibody. The data are shown as the ratio of D 3 receptor immunoprecipitate/AT 1 receptor immunoblot and D 3 receptor immunoprecipitate/D 3 receptor immunoblot. To determine the specificity of the bands, normal rabbit IgG (negative control) and AT 1 receptor antibody (positive control) were used as the immunoprecipitates instead of the D 3 receptor antibody. 21 In another series of experiments, we reversed the antibodies used for immunoprecipitation and immunoblotting. The samples were immunoprecipitated with the AT 1 receptor antibody and divided into 2 aliquots. One was immunoblotted with the D 3 receptor antibody and the other was immunoblotted with the AT 1 receptor antibody. The data are shown as the ratio of AT 1 receptor immunoprecipitate/D 3 receptor immunoblot and AT 1 receptor immunoprecipitate/ AT 1 receptor immunoblot. To determine the specificity of the bands, normal rabbit IgG (negative control) and D 3 receptor antibody (positive control) were used as the immunoprecipitates instead of the AT 1 receptor antibody. 21
Immunofluorescence Microscopy
RPT cells, treated with vehicle or PD128907 (10 Ϫ7 mol/L) for 24 hours at 37°C, as above, were fixed and permeabilized as reported. 31 The D 3 receptor was visualized using an IgG affinity-purified polyclonal rabbit anti-rat D 3 receptor antibody followed by Alexa 488 -goat anti-rabbit IgG antibody (Molecular Probes, Eugene, Ore). The AT 1 receptor was visualized using a mouse anti-AT 1 receptor monoclonal antibody (Abcam Limited, Cambridgeshire, UK), followed by an Alexa Fluor 568 -goat anti-mouse IgG antibody (Molecular Probes). Immunofluorescence images were acquired (Olympus AX70 laser confocal microscopy) at an excitation wavelength of 480 nm and 560 nm; emission was detected at 535 and 645 nm. Cells that were treated with only Alex 488 -goat anti-rabbit IgG or Alexa Fluor 568 -goat anti-mouse IgG antibodies revealed no immunofluorescence, and omission of the anti-AT 1 antibody showed no red or yellow color after merging (data not shown).
Statistical Analysis
The data were expressed as meanϮSEM. Comparison within groups was made by ANOVA for repeated measures (or paired t test when only 2 groups were compared), and comparison among groups (or t test when only 2 groups were compared) was made by ANOVA with Duncan's test. Corresponding periods between 2 different groups were analyzed by independent t test. A value of PϽ0.05 was considered significant.
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Results
D 3 Receptors Decrease AT 1 Receptor Expression in WKY RPT Cells and Increase It in SHR RPT Cells
The D 3 receptor agonist PD128907 decreased AT 1 receptor expression in a concentration-and time-dependent manner.
The inhibitory effect was evident at 10 Ϫ10 mol/L with a 50% decrease (EC 50 ) in AT 1 receptor expression at 7.3ϫ10 Ϫ10 mol/L ( Figure 1A) . The inhibitory effect of PD128907 (10 Ϫ7 mol/L) was noted as early as 2 hours and maintained for at least 24 hours; a 50% decrease (t 1/2 ) in AT 1 receptor expression occurred at 7.1 hours ( Figure 1B Figure 1C ). The specificity of PD128907 16 as a D 3 receptor agonist was also determined by studying the effect of the D 3 receptor antagonist U99194. 27 Consistent with the study shown in Figure 1A and 1B, PD128907 (10 Ϫ7 mol/L per 24 hours), decreased AT 1 receptor expression (controlϭ1.2Ϯ0.1 DU, PD128907ϭ0.6Ϯ0.1 DU, nϭ5; PϽ0.05). The D 3 receptor antagonist, U99194 (10 Ϫ5 mol/L), by itself, had no effect on AT 1 receptor expression (U99194ϭ1.2Ϯ0.1 DU) but reversed the inhibitory effect of PD128907 on AT 1 receptor expression (PD128907ϩU99194ϭ1.1Ϯ0.1 DU, nϭ5) ( Figure 1D ).
To investigate a mechanism for D 3 receptor downregulation of AT 1 receptor, the RPT cells from WKY and SHRs were treated with PD128907 for 24 hours. Activation of the Figure 1E ).
D 3 Receptor Agonist Increases D 3 Receptor Expression in WKY RPT Cells, Not in SHR Cells
To investigate the effect of a D 3 receptor agonist on its own receptor, RPT cells from SHR and WKY rats were incubated with the D 3 receptor agonist, PD128907 (10 Ϫ7 mol/L), for 24 hours. Immunoblots showed that the D 3 receptor agonist increased its own receptor expression in WKY RPT cells, not in SHR cells (WKY: controlϭ1.1Ϯ0.2, PD128907ϭ1.8Ϯ0.2; SHR: controlϭ0.7Ϯ0.15, PD128907ϭ0.6Ϯ0.2; PϽ0.05, nϭ13), and the basal level of D 3 receptor protein expression was higher in WKY cells than in SHR cells ( Figure 2 ).
D 3 Receptor Colocalizes With the AT 1 Receptor in Rat RPT Cells
To determine whether there is a potential for a direct or an indirect interaction between D 3 and AT 1 receptors, we studied the colocalization of D 3 and AT 1 receptors in rat RPT cells using immunofluorescence laser confocal microscopy. Both D 3 receptor and AT 1 receptor were found throughout the whole cell. It was also evident that the D 3 receptor and AT 1 receptor colocalized in these cells, especially in the cellular membrane (Figure 3 ).
To determine whether there is a physical interaction between the D 3 and the AT 1 receptors, additional experiments were performed. When D 3 receptors were immunoprecipitated with the D 3 receptor antibody and immunoblotted with the AT 1 receptor antibody, and the data were normalized by D 3 receptor immunoprecipitated and immunoblotted with D 3 receptor antibody ( Figure 4A ), basal coimmunoprecipitation levels were higher in WKY than in SHR cells. However, D 3 receptor stimulation with PD128907 decreased the percent amount of D 3 receptors that coimmunoprecipitated with AT 1 receptors to a greater extent in WKY than in SHR cells ( Figure 4A : WKY: controlϭ1.4Ϯ0.15 DU, PD128907ϭ0.4Ϯ0.2 DU; SHR: controlϭ0.5Ϯ0.1 DU, PD128907ϭ0.25Ϯ0.06 DU, PϽ0.05, nϭ5). This occurred because PD128907 increased D 3 receptor expression in WKY but not in SHR cells. 32 When AT 1 receptors were immunoprecipitated with the AT 1 receptor antibody and immunoblotted with the D 3 receptor antibody, and the data normalized by AT 1 receptor immunoprecipitated and immunoblotted with AT 1 receptor antibody ( Figure 4B ), basal coimmunoprecipitation levels were also higher in WKY than in SHR cells, in agreement with the results shown in Figure 4A . However, D 3 receptor stimulation with PD128907 did not change the percent amount of AT 1 receptors that coimmunoprecipitated with D 3 receptors in WKY cells because PD128907 decreased AT 1 receptor protein in WKY cells ( Figure 4B ) (WKY: con-trolϭ1.1Ϯ0.2 DU, PD128907ϭ1.3Ϯ0.1 DU; SHR: con-trolϭ0.4Ϯ0.05 DU, PD128907ϭ0.15Ϯ0.04 DU; PϽ0.05, nϭ5). In the SHR, D 3 receptor stimulation with PD128907 markedly decreased the coimmunoprecipitation because PD128907 increased AT 1 receptor protein in SHR cells.
AT 1 Receptor Expression Is Increased in the Kidneys of D 3 Receptor-Null Mice
To determine whether the apparent D 3 regulation of AT 1 receptors in vitro occurred in vivo, we determined AT 1 receptor expression in D 3 receptor-null mice. We have reported that arterial blood pressure and renin release were increased in D 3 receptor-null mice in mixed B129 and C57BL/6 background. 18 The ability of the homozygous D 3 receptor-null mice to excrete an acute sodium load was also impaired.
In the current study, we found that pentobarbital-anesthetized homozygous D 3 receptor-null mice, in C57BL/6 background, had higher systolic (SBP) and diastolic (DBP) blood pressures (SBPϭ117Ϯ5 and DBPϭ85Ϯ2 mm Hg; nϭ5) than wild-type C57BL/6 mice (SBPϭ94Ϯ2 and DBPϭ69Ϯ3 mm Hg; nϭ5; PϽ0.05, t test). Immunoreactive AT 1 receptors were also greater in the kidneys of D 3 receptor-null mice than in wild-type C57BL/6 mice (null mice, 1.4Ϯ0.1 DU; wild-type mice, 0.7Ϯ0.1 DU; nϭ5) ( Figure 5 ). To determine whether there was any effect of the D 3 receptor on vascular AT 1 receptor expression, we treated A10 cells with different concentrations of the D 3 receptor agonist PD128907 (10 Ϫ10 mol/L to 10 Ϫ6 mol/L). We found that stimulation of the D 3 receptor had no effect on AT 1 receptor expression in A10 cells ( Figure 6 ).
Discussion
There are several novel observations in our study. First, we showed that a D 3 receptor agonist PD128907 16 decreased AT 1 receptor protein and mRNA expression in rat WKY RPT cells; in contrast, the D 3 receptor agonist increased AT 1 receptor expression in SHR RPT cells. This effect was clearly exerted at the D 3 receptor because a D 3 receptor antagonist, U99194, 27 blocked the effect of the D 3 receptor agonist. Second, the D 3 receptor agonist increased D 3 receptor protein expression in WKY cells but had no effect in SHR cells. Third, AT 1 receptor expression was increased in the kidneys of D 3 receptor-null mice. Fourth, we demonstrated that D 3 receptors colocalized and coimmunoprecipitated with AT 1 receptors in rat RPT cells. D 3 receptor stimulation with PD128907 decreased the percent amount of D 3 receptors that coimmunoprecipitated with AT 1 receptors to a greater extent in WKY than in SHR cells. However, D 3 receptor stimulation did not change the percent amount of AT 1 receptors that coimmunoprecipitated with D 3 receptors in WKY cells and markedly decreased the coimmunoprecipitation in SHR cells.
Several studies have shown that the dopaminergic and renin/angiotensin systems interact to regulate renal function. [11] [12] [13] 26 As stated in the introduction, sodium transport in the kidney, especially in the luminal membrane of the proximal tubule, is reciprocally regulated by these systems. For example, dopamine, via D 1 -like receptors, antagonizes the stimulatory effects of angiotensin II on Na ϩ uptake in rat RPTs and brush border membrane vesicles. 13 Also, angiotensin-converting enzyme inhibition or an AT 1 receptor blockade enhances the natriuretic effect of a D 1 -like agonist. 11 The renal vasoconstrictor effect of angiotensin II can also be antagonized by D 1 -like receptor agonists. 8 The effect of the D 2 -like receptor, by itself, on renal sodium transport is controversial: stimulation, no effect, and even inhibition have been reported. 8 However, under certain circumstances, such as during moderate sodium loading, D 1and D 2 -like receptors can synergistically inhibit sodium transport. 25 The inhibitory effect of dopamine on sodium transport can be antagonized by both D 1 -like and D 2 -like receptor blockers. 13, 25, 33 A D 2 -like agonist, bromocriptine, has also been reported to antagonize the stimulatory effect of angiotensin II on Na ϩ /K ϩ -ATPase activity in RPTs. 12 The mechanism for the antagonistic effect of D 2 -like receptors on angiotensin II action is not well understood. Aminochrome, a metabolite of the dopamine oxidative pathway, has been reported to decrease AT 1 expression in a dopaminergic neuronal cell line RCSN3 of rat substantia nigra. 34 Bromocriptine, a D 2 -like agonist, has also been reported to decrease AT 1 receptor expression in rat RPTs. 12 However, because bromocriptine has equal affinity to D 2 and D 3 receptors, 16 it is not known which D 2 -like receptor mediates the inhibitory effect of bromocriptine on AT 1 receptor expression in rat RPTs.
The current studies show that the D 3 receptor participates in the regulation of AT 1 receptor expression in RPT cells. A role for D 2 receptors cannot be excluded because D 2 receptors are also expressed in rat renal cortex. 8 However, the D 2 receptors expressed in rat RPTs are probably prejunctional because D 2 receptor mRNA is not detected in the immortalized rat RPT cells (unpublished observations). It is also not clear whether the inhibitory effect of D 3 receptors on AT 1 receptor expression is direct or indirect. The D 3 receptor, but probably not the D 2 receptor, is the D 2 -like receptor that inhibits renin release. 18 Thus, plasma renin levels are elevated in D 3 receptor-null mice but not in D 2 receptor-null mice. 18, 19 Because RPT cells can also generate angiotensin II, 25, 35 it is possible that a D 3 receptor-mediated decrease in angiotensin II formation could have led to the decrease in AT 1 receptor expression because angiotensin II has been reported to increase AT 1 receptor mRNA in RPTs. 36 However, long-term infusion of angiotensin II in vivo in rats has no effect on AT 1 receptor expression in RPTs. 37 We also have preliminary observations indicating that AT 1 receptor expression in immortalized RPT cells is not increased by incubation with angiotensin II. 26 We, therefore, suggest that D 3 receptors, independent of angiotensin II, can regulate AT 1 receptor expression.
The mechanism for the decrease in AT 1 receptors caused by D 3 receptors was also investigated in this study. Stimulation of the D 3 receptor for 24 hours decreases AT 1 receptor mRNA expression in WKY cells but increases it in SHR cells. This result is consistent with AT 1 receptor protein result and indicates that the regulation of D 3 receptors on AT 1 receptor expression may occur at the transcriptional/posttranscriptional level. The decrease in AT 1 receptor protein expression at 2 hours, however, is probably not attributable to alterations at the transcriptional/posttranscriptional level. In the SHRs, renal G protein-coupled receptor kinase 4 (GRK4) expression and activity are increased 38 and may be responsible for the impaired D 1 receptor function in the kidney and hypertension. The GRK4 variant, A142V, but not GRK4 wild-type transgenic mice have increased AT 1 receptor protein. 39 We have preliminary data indicating that the D 5 dopamine receptor increases the degradation of the AT 1 receptor. 40 Therefore, the possibility that the D 3 receptor directly or indirectly increases the degradation of the AT 1 receptor cannot be ruled out. In SHRs, the decreased expression of D 3 receptor, even if constitutively active, may not be sufficient to impair the degradation of AT 1 receptor and, thus, the absence of a difference in total cell AT 1 receptor expression between WKY and SHRs. Stimulation of D 3 receptors would assist in the degradation of AT 1 receptors in WKY rats, but this does not occur in SHRs, hence the increase in AT 1 receptor protein with D 3 receptor stimulation in the latter rat strain. In addition, in the SHRs, stimulation of an altered D 3 receptor (secondary to increased GRK4 activity) may be responsible for the increase in AT 1 receptor mRNA.
We found by both morphological (confocal microscopy) and biochemical (immunoprecipitation) methods that D 3 and AT 1 receptors can directly interact with each other. When D 3 /AT 1 receptor coimmunoprecipitation is normalized by D 3 receptor or AT 1 receptor, the basal levels of D 3 /AT 1 receptor coimmunoprecipitation are higher in WKY cells as compared with SHR cells. However, when data of D 3 /AT 1 receptor coimmunoprecipitation are normalized by D 3 or AT 1 receptor, the ratios are different. Normalization by D 3 receptor shows that stimulation with PD128907 decreases the percent amount of D 3 receptors that coimmunoprecipitate with AT 1 receptors to a greater extent in WKY than in SHR cells. This occurs because PD128907 increases D 3 receptor expression in WKY but not in SHR cells. 32 Normalization of the data with AT 1 receptor shows that PD128907 does not change the D 3 /AT 1 receptor coimmunoprecipitation in WKY cells but markedly decreases it in SHR cells.
Taking into account that PD128907 increases D 3 receptor expression but decreases AT 1 receptor expression in WKY cells, we suggest that in WKY cells, PD128907 decreases the amount of D 3 receptors bound to AT 1 receptors while keeping the same amount of AT 1 receptors bound to the D 3 receptor. Therefore, more D 3 receptors can exert their effects while keeping AT 1 receptors in check; D 3 receptors are available to inhibit sodium reabsorption, and fewer AT 1 receptors are available to increase sodium reabsorption in RPTs in WKY rats.
In SHR cells, PD128907 increases AT 1 receptor expression but does not affect D 3 receptor expression. The data in Figure 4A and 4B suggest that D 3 receptor stimulation with PD128907 makes more AT 1 receptors than D 3 receptors available to exert their effects, more sodium reabsorption is 1 consequence. D 3 receptor-null mice in a C57BL/6 background have higher blood pressures than wild type C57BL/6 mice, confirming our previous study of D 3 receptor-deficient mice with mixed B129 and C57BL/6 18 background. The D 3 receptor-deficient mice in the previous study have increased renal renin activity, and their blood pressures are normalized by AT 1 receptor blockade with losartan. 18 It was not determined in the previous study whether the hypertension in the D 3 knockout mice is caused by an increase in angiotensin II levels and/or an increase in AT 1 receptors. Consistent with the ability of D 3 receptors to inhibit AT 1 receptor expression in immortalized RPT cells, AT 1 receptor expression is increased in the kidneys of D 3 receptor-null mice. It is, therefore, likely that the hypertension in D 3 receptor-null mice is also related to an increase in AT 1 receptor expression.
In summary, we have demonstrated that the D 3 receptor regulates AT 1 receptor expression in vivo and in vitro. It increases its own expression but decreases AT 1 receptor expression in RPT cells from normotensive WKY rats. In contrast, in RPT cells from SHRs, the D 3 receptor no longer regulates its own expression and actually increases AT 1 receptor expression. D 3 and AT 1 receptors colocalize and coimmunoprecipitate in RPT cells. Basal D 3 and AT 1 receptor coimmunoprecipitation is greater in WKY than SHR cells, but PD128907 had different effects on the percent amount of D 3 or AT 1 receptor that coimmunoprecipitated with the other receptor. It is possible that an impaired interaction between D 3 and AT 1 receptors play a role in the pathogenesis of genetic hypertension.
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